Get Tested
Get Tested

Ovarian Cancer Testing

Better diagnostics with molecular testing that can improve outcomes for women with ovarian cancer

Ovarian cancer has proved tricky to detect. There are no signs and symptoms of ovarian cancer at the early stages, and the American Cancer Society reports that only about 20 percent of cases are caught early.

However, the earlier you are diagnosed, the more likely you are to have a full recovery. When ovarian cancer is detected early, before it spreads, 90 percent of women can fully recover. That’s why improving early detection with UniDX’s OVA1plus ovarian cancer molecular test is so essential.

This test is available for women with an adnexal mass in the New York area at UniDX, located in Harlem, and is covered by Medicaid.

UniDX’s OVA1plus test has a superior rate of detection of ovarian cancer over CA-125 in Black women with an adnexal mass, especially.

  • OVA1 has a16.7 – 46 percent higher rate of detection (sensitivity) for ovarian malignancy vs. CA-125 in Black women.
  • OVA1 has a 25 percent higher rate of detection (sensitivity) for ovarian malignancy vs. ROMA (CA-125 & HE4) in white women.

Physicians can order this test for patients by emailing Help@UniDX.com.

How OvaLab’s ovarian cancer test improves diagnosis for Black women with an adnexal mass

Instead of relying only on the CA-125 blood marker, the OVA1plus test uses multiple variables to create an overall profile of your risk of having ovarian cancer.
The OVA1plus test is more accurate than other ovarian cancer tests for non-white women, especially Black women, since they naturally have lower levels of CA-125. An abnormal result on the OVA1plus means that you need to see a gynecologic oncology specialist who can perform a biopsy.
There’s no reason that any woman should have to suffer lower health outcomes due to poor testing. The OVA1plus ovarian cancer risk profile can help all women in the New York area to get an accurate assessment of malignancy, especially in the early stages of ovarian cancer.
The OVA1plus test is better testing for ovarian cancer that brings peace of mind, with 96 percent sensitivity of malignancy with clinical assessment and a 98 percent negative predictive value.
Click here to learn more

How UniDX’s test for ovarian cancer works

OVA1plus is made of OVA1 + OVERA tests
OVA1 evaluates the levels of five ovarian cancer-associated markers in blood:
  • Apolipoprotein - Cholesterol Transport
  • Beta 2 macroglobulin: host immune response
  • CA - 125Ⅱ: released by tumor cells
  • Prealbumin: Hormone and vitamin transport
  • Transferrin: iron transport
The levels are combined into a single cancer risk score.

Overa incorporates two new markers:

  • Human Epididymis protein 4: released by tumor cells
  • Follicle Stimulating Hormone: hormone regulation
Overa has a global platform and increased specificity.
OVA1plus has four major benefits:
  • Sensitivity across all ovarian cancer stages
  • Sensitivity across histological subtypes
  • Sensitivity across all ethnicities

At UniDX, we offer several different lab services, including an ovarian cancer diagnostic testing, to help women throughout New York City access more information about their health. Call us today or click here to schedule a fast and easy appointment for lab services. Our kind and compassionate female clinicians are experienced providers of laboratory services and can help you both detect and prevent a wide number of common conditions. To book an appointment for lab services, call our office today or visit our clinic conveniently located at 321 W 125th St. and 2406 Frederick Douglass Blvd.

Are you a woman living in New York City concerned about ovarian cancer? Talk to your doctor about scheduling an OVA1plus test at OvaLab today. The test is covered by Medicaid.

Physicians can order this test for patients by emailing Help@UniDX.com.

UniDX © 2024

Twitter
Links
Contact Info